Abstract
Intravenous heparin, a fundamental therapy in the treatment of patients with acute coronary syndromes, acts by inhibiting thrombin and activated factors X, IX, XI, and XII. It has also been demonstrated that heparin reduces plasma fibrinopeptide A, a marker of thrombin activity, but it is unknown whether it decreases prothrombin fragment 1+2, an indirect marker of thrombin generation. We measured the plasma levels of prothrombin fragment 1+2, fibrinopeptide A, and antithrombin III in 64 consecutive patients with unstable angina or myocardial infarction receiving intravenous heparin. Blood samples were obtained at baseline (before any treatment) and then at 90 minutes and 24 and 48 hours after the administration of an intravenous bolus of heparin (5000 IU) followed by a continuous infusion of 1000 IU per hour to maintain activated partial thromboplastin time at more than double its baseline levels. In comparison with baseline, there was a significant decrease in fibrinopeptide A at 90 minutes and at 24 and 48 hours (baseline, 2.3 nmol/L; 90 minutes, 1.15 nmol/L; 24 hours, 1.4 nmol/L; 48 hours. 1.2 nmol/L; P
| Original language | English |
|---|---|
| Pages (from-to) | 1325-1330 |
| Number of pages | 6 |
| Journal | Arteriosclerosis, Thrombosis, and Vascular Biology |
| Volume | 17 |
| Issue number | 7 |
| Publication status | Published - 1997 |
Fingerprint
Keywords
- Angina
- Myocardial infarction
- Thrombin
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
Cite this
Persistent thrombin generation during heparin therapy in patients with acute coronary syndromes. / Merlini, Piera Angelica; Ardissino, Diego; Bauer, Kenneth A.; Oltrona, Luigi; Pezzano, Antonio; Bottasso, Biancamaria; Rosenberg, Robert D.; Mannucci, Pier Mannuccio.
In: Arteriosclerosis, Thrombosis, and Vascular Biology, Vol. 17, No. 7, 1997, p. 1325-1330.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Persistent thrombin generation during heparin therapy in patients with acute coronary syndromes
AU - Merlini, Piera Angelica
AU - Ardissino, Diego
AU - Bauer, Kenneth A.
AU - Oltrona, Luigi
AU - Pezzano, Antonio
AU - Bottasso, Biancamaria
AU - Rosenberg, Robert D.
AU - Mannucci, Pier Mannuccio
PY - 1997
Y1 - 1997
N2 - Intravenous heparin, a fundamental therapy in the treatment of patients with acute coronary syndromes, acts by inhibiting thrombin and activated factors X, IX, XI, and XII. It has also been demonstrated that heparin reduces plasma fibrinopeptide A, a marker of thrombin activity, but it is unknown whether it decreases prothrombin fragment 1+2, an indirect marker of thrombin generation. We measured the plasma levels of prothrombin fragment 1+2, fibrinopeptide A, and antithrombin III in 64 consecutive patients with unstable angina or myocardial infarction receiving intravenous heparin. Blood samples were obtained at baseline (before any treatment) and then at 90 minutes and 24 and 48 hours after the administration of an intravenous bolus of heparin (5000 IU) followed by a continuous infusion of 1000 IU per hour to maintain activated partial thromboplastin time at more than double its baseline levels. In comparison with baseline, there was a significant decrease in fibrinopeptide A at 90 minutes and at 24 and 48 hours (baseline, 2.3 nmol/L; 90 minutes, 1.15 nmol/L; 24 hours, 1.4 nmol/L; 48 hours. 1.2 nmol/L; P
AB - Intravenous heparin, a fundamental therapy in the treatment of patients with acute coronary syndromes, acts by inhibiting thrombin and activated factors X, IX, XI, and XII. It has also been demonstrated that heparin reduces plasma fibrinopeptide A, a marker of thrombin activity, but it is unknown whether it decreases prothrombin fragment 1+2, an indirect marker of thrombin generation. We measured the plasma levels of prothrombin fragment 1+2, fibrinopeptide A, and antithrombin III in 64 consecutive patients with unstable angina or myocardial infarction receiving intravenous heparin. Blood samples were obtained at baseline (before any treatment) and then at 90 minutes and 24 and 48 hours after the administration of an intravenous bolus of heparin (5000 IU) followed by a continuous infusion of 1000 IU per hour to maintain activated partial thromboplastin time at more than double its baseline levels. In comparison with baseline, there was a significant decrease in fibrinopeptide A at 90 minutes and at 24 and 48 hours (baseline, 2.3 nmol/L; 90 minutes, 1.15 nmol/L; 24 hours, 1.4 nmol/L; 48 hours. 1.2 nmol/L; P
KW - Angina
KW - Myocardial infarction
KW - Thrombin
UR - http://www.scopus.com/inward/record.url?scp=0030762623&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0030762623&partnerID=8YFLogxK
M3 - Article
C2 - 9261263
AN - SCOPUS:0030762623
VL - 17
SP - 1325
EP - 1330
JO - Arteriosclerosis, Thrombosis, and Vascular Biology
JF - Arteriosclerosis, Thrombosis, and Vascular Biology
SN - 1079-5642
IS - 7
ER -